-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Initiates Coverage On Bicara Therapeutics with Market Outperform Rating, Announces Price Target of $31

Benzinga·01/29/2026 13:59:59
Listen to the news
Citizens analyst Reni J. Benjamin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform rating and announces Price Target of $31.